Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lophius Biosciences Performs Successful Clinical Validation for T-Track® CMV/EBV Test Systems

Published: Thursday, April 26, 2012
Last Updated: Wednesday, April 25, 2012
Bookmark and Share
Both systems aim to increase transplantation outcome and reduce negative therapeutic effects.

Lophius Biosciences has announced the successful completion of a prospective multicenter clinical validation study for its T-Track® CMV/EBV tests.

In cooperation with four dialysis centers in Germany (Regensburg, Mannheim, Straubing and Landshut) the ability of both T-Track® CMV/EBV tests with respect to determination of functional effector cells of cell-mediated immunity was successfully examined during 4th quarter 2011 in a cohort of > 120 hemodialysis patients.

Using standard statistical analysis tools, the clinical sensitivities were 100% for T-Track® CMV and 97% for T-Track® EBV in this cohort.

Based on the study results Lophius Biosciences was able to develop a novel simple biostatistical method for T-cell based tests, which should allow comparative analysis between different patient groups in the future.

This is a key prerequisite for the use of both T-Track® CMV/EBV tests for a routine immune monitoring. Using this novel tool, clinical sensitivities were 88% for T-Track® CMV and 86% for T-Track® EBV.

“We were very impressed with the high clinical sensitivities for both T-Track® CMV and T-Track ® EBV Tests“, said Prof. Dr. Bernhard Banas, Department Head of Nephrology und Transplantation Center of the University Hospital Regensburg.

Prof. Banas continued, “In connection with its high degree of standardization, both test systems may be key for a personalized therapy in transplantation medicine, with the aim to increase transplantation outcome and reduce negative therapeutic effects”.

“We are delighted that we were able as part of the validation study to develop an analysis tool for the first time that may set the basis for a standardized measurement of cell-mediated immune response. This should allow a user-friendly monitoring of the immune status of immune compromized patients e.g. after transplantation, but also in other indications” added PD Dr. Ludwig Deml, CSO of Lophius Biosciences.

Dr. Michael Lutz, CEO of Lophius Biosciences, said: “The successful completion of both test developments for both T-Track® CMV and T-Track® EBV tests in a short timeframe underpins the high innovative potential of our proprietary technology platform. This could set the basis for novel T-cell based diagnostic systems in areas with high medical need”.

Lophius Biosciences will present the study results at the world biggest transplantation conference (TTS) in Berlin in July 2012.

Moreover, the company aims to publish the study results as quickly as possible in a leading scientific journal.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lophius Biosciences Appoints Dr. Robert Phelps as Director Business Operations
Dr. Phelps has longstanding experience in business development and licensing.
Wednesday, December 04, 2013
Lophius Biosciences Joins NEU² Program
Company receives substantial grant funding for the diagnosis and monitoring of multiple sclerosis.
Wednesday, June 19, 2013
Lophius Biosciences Closes Financing Round and Expands Management Board
Lophius Biosciences announces the closing of a further financing round with Prof. Dr Ralf Wagner been appointed as Managing Director.
Tuesday, January 22, 2013
Lophius Biosciences Concludes TB Detection Trials
Company achieves first clinical Proof of Principle for T-Track® TB for detection of active tuberculosis and receives research funding.
Thursday, November 08, 2012
Lophius Biosciences Completes Necessary Regulatory Milestones with EN ISO 13485 Certification
Company has received CE-marking for its T-Track® CMV and T-Track® EBV tests.
Friday, June 01, 2012
Lophius Biosciences Closes Additional Financing Round with Current Investors Totaling 1.4 Million EUR
Financial investors such as S-Refit, High-Tech Gründerfonds and Bayernkapital participated in this financing round.
Tuesday, July 19, 2011
Lophius Biosciences Expands its Management Team and Prepares for Market Entry at the Beginning of 2012
The team is completed by Dr. Zanker from MedicalDevice+, an experienced expert in the field of regulatory affairs for diagnostic products.
Tuesday, July 12, 2011
Scientific News
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment
Experimental method uses genetics-guided biomechanics, patient-specific stem cells.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Fast, Simple Test for Colitis
A minimally invasive screening for ulcerative colitis using emerging infrared technology could be a rapid and cost-effective method for detecting disease that eliminates the need for biopsies and intrusive testing of the human body.
Scans Reveal Babies of Mothers with Gestational Diabetes Have More Body Fat
Researchers at Imperial College London have found that the babies born to mothers with gestational diabetes have more body fat at two months of age compared to babies born to healthy mothers.
New Device Could Improve Cancer Detection
UBC researchers develop a microfluidic device to capture circulating tumor cells.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!